https://resilience-h2020.com/

RESILIENCE

Inclusion criteria

- ✓ ≥18 years old.
- ✓ First Lymphoma diagnosis
- ✓ Scheduled to undergo ≥5 chemotherapy cycles including anthracyclines
- ✓ Pre-chemo LVEF >40% on screening echocardiography.
- ✓ Sinus rhythm on screening ECG.
- ✓ Presence of ≥1 of the following risk factors for developing cardiotoxicity:
  - ✓ Previous coronary artery disease (any of the following):
    - ✓ Previous coronary revascularisation (PCI or CABG) or Medical history of previous significant non-revascularized coronary stenosis
    - ✓ Previous Acute Coronary Syndrome / Acute Myocardial Infarction with a LVEF > 40
  - ✓ LVEF 41-54%
  - ✓ Age ≥ 65 years old
  - ✓ Previous diagnosis of arterial hypertension (with or without treatment)
  - ✓ Chronic kidney disease (estimated glomerular filtration rate <60ml/min/1.73m2)
  - ✓ Current or former smoker.
  - ✓ Obesity (BMI≥30 kg/m2)
  - ✓ LVH on screening echocardiography (LV thickness ≥12mm).
  - ✓ High alcohol intake (≥21 alcoholic beverages per week)
  - ✓ Previous diagnosis of diabetes (except those treated with sulfonylureas or those with neuropathy)
  - ✓ Previous non-anthracycline-based chemotherapy
- ✓ Signed informed consent form.

Exclusion criteria

- ✗ History of any of the following diseases:
  - ✗ Any cancer who received anthracyclines treatment before the index episode.
  - ✗ Previous clinical diagnosis of heart failure.
  - ✗ Permanent atrial fibrillation (AF).
  - ✗ Severe valvular or sub-valvular heart disease.
  - ✗ Severe peripheral arterial disease in the upper extremities or arteriovenous (AV) shunt in the arm selected for RIC.
  - ✗ Diabetic neuropathy
  - ✗ Diabetes actively treated with sulfonylureas
- ✗ Contraindication for CMR:
  - ✗ Severe claustrophobia.
  - ✗ Any device which is known to threaten or pose hazard in all MR environments (http://www.mrisafety.com/).
  - ✗ Patients with implanted biomedical cardiac devices: pacemakers, ICDs or CRT.
- ✗ Severe thrombocytopenia (platelets <50,000/µL) on any blood test within the previous 3 months.
- ✗ Patients participating in other randomized clinical trials.
- ✗ Impossibility to consent or undergo study follow-ups.

The RESILIENCE project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945118